Rapid Therapeutic Science Laboratories, Inc. (RTSL) Notes Payables (2017 - 2023)
Rapid Therapeutic Science Laboratories' Notes Payables history spans 6 years, with the latest figure at $841560.0 for Q2 2023.
- For Q2 2023, Notes Payables rose 19.08% year-over-year to $841560.0; the TTM value through Jun 2023 reached $841560.0, up 19.08%, while the annual FY2022 figure was $820602.0, 25.38% down from the prior year.
- Notes Payables for Q2 2023 was $841560.0 at Rapid Therapeutic Science Laboratories, up from $829988.0 in the prior quarter.
- Across five years, Notes Payables topped out at $1.9 million in Q1 2022 and bottomed at $23350.0 in Q1 2020.
- The 4-year median for Notes Payables is $725750.0 (2022), against an average of $637862.7.
- The largest annual shift saw Notes Payables crashed 97.23% in 2021 before it surged 7765.84% in 2022.
- A 4-year view of Notes Payables shows it stood at $674927.0 in 2020, then soared by 62.94% to $1.1 million in 2021, then decreased by 25.38% to $820602.0 in 2022, then grew by 2.55% to $841560.0 in 2023.
- Per Business Quant, the three most recent readings for RTSL's Notes Payables are $841560.0 (Q2 2023), $829988.0 (Q1 2023), and $820602.0 (Q4 2022).